By: Thomas Powles, MD Date: October 25, 2023 An exclusive interview occurred with Dr. Thomas Powles, MD, the lead investigator of the EV-302 phase 3 trial, where the discussion revolved around the Enfortumab Vedotin and Pembrolizumab combination and its potential impact on bladder cancer treatment. During the interview, Dr. Powles detailed how the Enfortumab Vedotin-Pembrolizumab … Continue reading Enfortumab Vedotin & Bladder Cancer: Thomas Powles, MD ESMO 2023